Baseline demographics and disease characteristics (FAS)
| Study population (n=76) | |
|---|---|
| Gender: male, n (%) | 26 (34) |
| Mean (SD) age, years | 54.4 (10.9) |
| Mean (SD) body mass index, kg/m2 | 25.1 (3.8) |
| Mean (SD) time since first diagnosis, years | 6.0 (6.2) |
| Mean (SD) estimated duration of CD, years | 9.2 (7.2) |
| Pretreated with BT for CD, n (%)* | 57 (75) |
| Mean (SD) number of injection sessions | 22.4 (20.7) |
| Mean (SD) time since start of treatment, years | 6.8 (5.5) |
| Mean (SD) TWSTRS scores at study baseline | |
| Total | 39.0 (10.3) |
| Severity | 18.3 (3.8) |
| Disability | 11.2 (5.1) |
| Pain | 9.5 (4.9) |
| Mean (SD) DDS score at study baseline† | 72.2 (26.2) |
| Swallowing difficulties at study baseline‡ (dysphagia scale score >0), n (%) | 7 (9) |
*Formulations received at the last injection session prior to study entry were incobotulinumtoxinA (n=32), abobotulinumtoxinA (n=14) or onabotulinumtoxinA (n=11).
†Baseline DDS scores were available for 71 patients.
‡The number of patients with swallowing difficulties at study baseline was based on the safety evaluation set (n=76).
BT, botulinum toxin; CD, cervical dystonia; DDS, Dystonia Discomfort Scale; FAS, full analysis set; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.